{
  "source": "PA-Notification-Takhzyro.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1263-8\nProgram Prior Authorization/Notification\nMedication Takhzyro® (lanadelumab-flyo)\nP&T Approval Date 11/10218, 11/2019, 11/2020, 11/2021, 11/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nTakhzyro is a plasma kallikrein inhibitor (monoclonal antibody) indicated for prophylaxis to\nprevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 2 years and\nolder.1\n2. Coverage Criteriaa:\nA. Hereditary Angioedema\n1. Initial Authorization\na. Takhzyro will be approved based on both of the following criteria:\n(1) Diagnosis of hereditary angioedema (HAE)\n-AND-\n(2) Both of the following:\n(a) For prophylaxis against HAE attacks\n-AND-\n(b) Not used in combination with other products indicated for prophylaxis against\nHAE attacks (e.g., Cinryze, Haegarda, Orladeyo)\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Takhzyro will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response while on Takhzyro therapy\n-AND-\nb. Both of the following:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(1) For prophylaxis against HAE attacks\n-AND-\n(2) Not used in combination with other products indicated for prophylaxis against HAE\nattacks (e.g., Cinryze, Haegarda, Orladeyo)\nAuthorization of therapy will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Takhzyro [package inse",
    "s (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Takhzyro [package insert]. Lexington, MA: Shire; February 2023.\nProgram Takhzyro® (lanadelumab-flyo)\nChange Control\n11/2018 New program\n11/2019 Annual review. Updated references.\n11/2020 Annual review. No changes.\n11/2021 Annual review. Updated combination examples to include Orladeyo with\nno change in clinical intent.\n11/2022 Annual review with no change to criteria. Added state mandate footnote.\nUpdated reference.\n3/2023 Updated background with expanded FDA indication in patients aged 2\nyears and older. Updated combination use language with prophylactic\ntherapies without change to clinical intent. Updated reference.\n3/2024 Annual review. No changes to coverage criteria.\n3/2025 Annual review. No changes to coverage criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}